Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
A 'better for you' organic brand spanning Food & Beverages and Nutraceutical categories
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
The Awards recognizes standout digital health & medical technology products and companies
Women of all ages will get round-the-clock access to comprehensive treatment
Subscribe To Our Newsletter & Stay Updated